A Study to Evaluate the Efficacy and Safety of AK127 in Patients With Advanced Solid Tumors

Akeso

Status and phase: Not yet enrolling; Phase 1

Conditions: Advanced Solid Tumors

Treatments: Drug: AK127

Study type: Interventional

Funder types: Industry

Identifiers

NCT05393063

AK127-102

Details and patient eligibility

About

This study is to characterize the safety, tolerability and anti-tumor activity of AK127 as a single agent in adult subjects with advanced solid tumor malignancies.

Full description

This study is to characterize the safety, tolerability, pharmacokinetics (PK), immunogenicity, pharmacodynamics (PD) and anti-tumor activity of AK127 as a single agent in adult subjects with advanced solid tumor malignancies. The study, as a dose escalation phase is to determine the maximum tolerated dose (MTD), or recommended Phase 2 dose (RP2D) for AK127 as a single agent, and describe Dose Limiting Toxicity (DLT).

Enrollment: 36 estimated patients

Sex: All

Ages: 18 to 75 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Ability to understand and voluntarily sign a written informed consent form (ICF), which must be signed before the specified study procedures required for the study are performed.
2. Males or females aged ≥ 18 to ≤ 75 years at the time of signing informed consent.
3. Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0 or 1.
4. Life expectancy ≥3 months.
5. Histologically or cytologically documented advanced or metastatic solid tumor that is refractory/relapsed to standard therapies, or for which no effective standard therapy is available, or the subject is not suitable for standard therapy.
6. Adequate organ function.
7. Patients of childbearing potential must agree to use effective contraceptive measures.

Exclusion criteria

1. The patient has received prior immunotherapy against TIGIT target.
2. Not currently enrolled in any other clinical study.
3. Receipt of any anticancer therapy within 4 weeks or within 5 half-lives of the drug prior to the first dose of AK127.
4. Symptomatic central nervous system metastases.
5. Active malignancies within the past 1 years, with the exception of tumors in this study and cured local tumors.
6. Active autoimmune disease requiring systemic treatment prior to the start of study treatment.
7. There is a history of major diseases 1 year prior to the first dose.
8. Medical history of gastrointestinal perforation or gastrointestinal fistula within 6 months prior to the first dose.
9. Received chest radiation therapy prior to the first dose.
10. Presence of clinically symptomatic pleural effusion, pericardial effusion, or ascites requiring frequent drainage.
11. Active or previously documented inflammatory bowel disease (e.g., Crohn's disease or ulcerative colitis).
12. Receipt of live or attenuated vaccination within 4 weeks prior to the first dose of AK127.
13. Known history of testing positive for human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (AIDS).
14. Known history of active tuberculosis.
15. History of organ transplant or hematopoietic stem cell.
16. History of primary immunodeficiency.
17. Any condition that, in the opinion of the investigator, would interfere with evaluation of the investigational product or interpretation of subject safety or study results.
18. Other cases deemed inappropriate by the investigator.

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

36 participants in 1 patient group

AK127

Experimental group

Description:

Subjects will receive AK127 by intravenous administration

Treatment:

Drug: AK127